Newsfeeds - Spark Newswire

1 minute read

Earnings

Exelixis: Q4 Earnings Insights

Today, 10:50 AM

Exelixis (NASDAQ:EXEL) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis beat estimated earnings by 483.33%, reporting an EPS of $0.35 versus an estimate of $0.06.

EXEL

10 minute read

Earnings Scheduled For February 17, 2022

By Benzinga Insights

Today, 10:50 AM

Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million.

AAWW

1 minute read

Earnings

Earnings Preview For Exelixis

By Benzinga Insights

Today, 10:50 AM

Exelixis (NASDAQ:EXEL) is set to give its latest quarterly earnings report on Thursday, 2022-02-17. Here's what investors need to know before the announcement. Analysts estimate that Exelixis will report an earnings per share (EPS) of $0.06.

EXEL

1 minute read

Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer Trial

By Vandana Singh

Today, 10:50 AM

Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL)

BMY

4 minute read

Bristol Myers Reports Opdivo In Combo With CABOMETYX Showed Continued Survival Benefits With 2+ Years Of Follow Up In CheckMate Trial For Advanced Renal Cell Carcinoma

By Benzinga Newsdesk

Today, 10:50 AM

compared to sunitinib Patients treated with Opdivo and CABOMETYX continue to report improvements in health-related quality of life in a separate analysis PRINCETON, N.J. & ALAMEDA, Calif.--(BUSINESS WIRE)-- Today

BMY

3 minute read

Tenaya Therapeutics Offers 2022 Business Updates

By Benzinga Newsdesk

Today, 10:50 AM

Company announces development candidate selection of its second gene therapy program, TN-401, targeting the leading genetic cause of arrhythmogenic right ventricular cardiomyopathy (gARVC) IND applications for

EXEL

1 minute read

Exelixis And Iconic Therapeutics Amend Option And License Agreement For XB002; Exelixis Gains Full Rights To Use Anti-TF Antibody Incorporated Into XB002 For Any Application, Will Make One-Time Payment Of $55M

By Bill Haddad

Today, 10:50 AM

Exelixis, Inc. (NASDAQ:EXEL) and Iconic Therapeutics, Inc. (Iconic) today announced that the companies have amended the terms of their May 2019 exclusive option and license agreement for XB002 (formerly

EXEL

3 minute read

The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review

By Shanthi Rexaline

Today, 10:50 AM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ADAG

1 minute read

News

Exelixis Granted U.S. Patent #11,198,731 ‘Combinations of cabozantinib and atezolizumab to treat cancer’

By Charles Gross

Today, 10:50 AM

View Patent here

EXEL

1 minute read

Analyst Ratings

Analyst Ratings For Exelixis

By Benzinga Insights

Today, 10:50 AM

Over the past 3 months, 5 analysts have published their opinion on Exelixis (NASDAQ:EXEL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

EXEL